Swiss pharmaceutical giant Roche agreed to pay $46.8 billion to buy the 44 percent of biotech pioneer Genentech that it doesn’t already own, ending a long corporate struggle with its U.S.-based cancer drug partner.
A Roche Research Associate commented “Company is losing plenty of talent due to their Genentech offer.”
See what other employees had to say in the days leading up to the final bid.
Roche said its Pharma commercial operations in the U.S. will be moved from Nutley, N.J., to Genentech’s site in South San Francisco, which will become headquarters of the combined company’s U.S. commercial operations in pharmaceuticals and operate under the Genentech name. In addition, Roche stated that research and early development will operate as an independent center within Roche from its existing campus in South San Francisco.
How will employees be impacted with this merger moving forward?